Journal: Molecules

Article Title: Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives

doi: 10.3390/molecules29194774

Figure Lengend Snippet: The inhibition of COL1A1 promotor of target compounds.

Article Snippet: The following reagents and antibodies were purchased for the study of the biological activity of the compounds: anti-COL1A1 antibody (ET1609-68) from HUABIO (Hangzhou, China); anti-fibronectin (ab2413), anti-TGFβ1 (ab179695), anti-Timp1 (ab211926) antibodies from Abnova (Boulder, CO, USA) and Abcam (Cambridge, UK); anti-GAPDH antibody (#5174), anti-IKKβ antibody (#2370), anti-P-IKKβ antibody (#2697), anti-NF-κB p65 antibody (#8242), anti-P-NF-κB p65 antibody (#3033) and anti-IL-6 antibody (#12153) from Cell Signaling Technology (Danvers, MA, USA), recombinant Human TGFβ1 Protein (240-B) from R & D Systems (Minneapolis, MN, USA), and LPS (L2880) from Sigma (Olney, MD, USA).

Techniques: Inhibition

Journal: Molecules

Article Title: Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives

doi: 10.3390/molecules29194774

Figure Lengend Snippet: Inhibition of the target compound on fibro-genic genes in LX-2 cells 24 h after TGFβ1 (2 ng/mL) induction. ( A ) Effects of 10 target compounds and L-Asp on the expression of fibro-genic genes after 24 h induction by TGFβ1, with GAPDH as the internal reference. ( B ) Western blot analysis of the effects of different concentrations of compounds 41 and 8a on TGFβ1-induced fibro-genic proteins. ( C ) The effects of 41 and 8a on the mRNA levels of COL1A1, TGFβ and MMP2 were analyzed by RT–qPCR. where the values were presented as the mean ± SD and GAPDH served as the internal control, n = 3; ## p < 0.01 vs. non-treated control, and * p < 0.05, ** p < 0.01 vs. TGFβ1 group.

Article Snippet: The following reagents and antibodies were purchased for the study of the biological activity of the compounds: anti-COL1A1 antibody (ET1609-68) from HUABIO (Hangzhou, China); anti-fibronectin (ab2413), anti-TGFβ1 (ab179695), anti-Timp1 (ab211926) antibodies from Abnova (Boulder, CO, USA) and Abcam (Cambridge, UK); anti-GAPDH antibody (#5174), anti-IKKβ antibody (#2370), anti-P-IKKβ antibody (#2697), anti-NF-κB p65 antibody (#8242), anti-P-NF-κB p65 antibody (#3033) and anti-IL-6 antibody (#12153) from Cell Signaling Technology (Danvers, MA, USA), recombinant Human TGFβ1 Protein (240-B) from R & D Systems (Minneapolis, MN, USA), and LPS (L2880) from Sigma (Olney, MD, USA).

Techniques: Inhibition, Expressing, Western Blot, Quantitative RT-PCR, Control

Journal: Molecules

Article Title: Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives

doi: 10.3390/molecules29194774

Figure Lengend Snippet: Inhibition effects on COL1A1 promoter of representative compounds.

Article Snippet: The following reagents and antibodies were purchased for the study of the biological activity of the compounds: anti-COL1A1 antibody (ET1609-68) from HUABIO (Hangzhou, China); anti-fibronectin (ab2413), anti-TGFβ1 (ab179695), anti-Timp1 (ab211926) antibodies from Abnova (Boulder, CO, USA) and Abcam (Cambridge, UK); anti-GAPDH antibody (#5174), anti-IKKβ antibody (#2370), anti-P-IKKβ antibody (#2697), anti-NF-κB p65 antibody (#8242), anti-P-NF-κB p65 antibody (#3033) and anti-IL-6 antibody (#12153) from Cell Signaling Technology (Danvers, MA, USA), recombinant Human TGFβ1 Protein (240-B) from R & D Systems (Minneapolis, MN, USA), and LPS (L2880) from Sigma (Olney, MD, USA).

Techniques: Inhibition